Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: A preliminary study as possible vaccine against genital herpes

被引:28
作者
Cortesi, Rita [1 ,2 ]
Ravani, Laura [1 ,2 ]
Rinaldi, Francesca [3 ]
Marconi, Peggy [3 ]
Drechsler, Markus [5 ]
Manservigi, Marco [3 ]
Argnani, Rafaela [3 ]
Menegatti, Enea [1 ,2 ]
Esposito, Elisabetta [1 ,2 ]
Manservigi, Roberto [3 ,4 ]
机构
[1] Univ Ferrara, Dept Pharmaceut Sci, I-44121 Ferrara, Italy
[2] Consortium TEFARCO Innova, Milan, Italy
[3] Univ Ferrara, Dept Diagnost & Expt Med, Microbiol Sect, I-44121 Ferrara, Italy
[4] Univ Ferrara, Ctr Biotechnol, I-44121 Ferrara, Italy
[5] Univ Bayreuth, Bayreuth, Germany
关键词
HSV-1; Niosomes; Specialized delivery systems; Vaccine; Intranasal immunization; SIMPLEX-VIRUS; DRUG-DELIVERY; GENETIC IMMUNIZATION; ANTIBODY-RESPONSES; NIOSOMES; DNA; PROTECTION; IMMUNITY; MICROSPHERES; INFECTIONS;
D O I
10.1016/j.ijpharm.2012.06.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice. NISV were prepared by lipid film hydration method. The mean diameter of vesicles was around 390 nm for DTK-containing NISV (DTK-NISV) and 320 nm for gB1s-containing NISV (gB1s-NISV). The encapsulation efficiency of the molecules was comprised between 57% and 70%. After 7-14 day NISV maintained stable dimensions and a drug encapsulation higher than 48%. We showed that intranasal immunization with gB1s-NISV induces gB-specific IgG antibody and lymphoproliferative responses, whereas vaccination with DTK-NISV was not able to generate a gB-specific immune response. Our results indicate that vaccination of BALB/c mice with gB1s-NISV induced Th1 responses, as characterized by increased titre of IG2a in plasma and IFN-production in CD4+ splenic cells. Intranasal immunization with gB1s-NISV could elicit 90% (almost complete) protection against a heterologous lethal vaginal challenge with herpes simplex virus type 2. These data may have implications for the development of a mucosal vaccine against genital herpes. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:229 / 237
页数:9
相关论文
共 52 条
[1]   Niosomes in sustained and targeted drug delivery: some recent advances [J].
Azeem, Adnan ;
Anwer, Md. Khalid ;
Talegaonkar, Sushama .
JOURNAL OF DRUG TARGETING, 2009, 17 (09) :671-689
[2]   Glycoprotein D adjuvant herpes simplex virus vaccine [J].
Bernstein, David .
EXPERT REVIEW OF VACCINES, 2005, 4 (05) :615-627
[3]   Herpes simplex virus vaccines [J].
Bernstein, DI ;
Stanberry, LR .
VACCINE, 1999, 17 (13-14) :1681-1689
[4]  
Biswal S., 2008, Int. J. Pharm. Sci. Nanotechnol, V1, P1, DOI DOI 10.37285/IJPSN.2008.1.1.1
[5]  
Brewer JM, 1998, J IMMUNOL, V161, P4000
[6]  
BREWER JM, 1992, IMMUNOLOGY, V75, P570
[7]   Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection [J].
Caselli, E ;
Grandi, P ;
Argnani, R ;
Balboni, PG ;
Selvatici, R ;
Manservigi, R .
INTERVIROLOGY, 2001, 44 (01) :1-7
[8]   Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection [J].
Caselli, E ;
Balboni, PG ;
Incorvaia, C ;
Argnani, R ;
Parmeggiani, F ;
Cassai, E ;
Manservigi, R .
VACCINE, 2000, 19 (9-10) :1225-1231
[9]   Physicochemical characterization of influenza viral vaccine loaded surfactant vesicles [J].
Chattaraj, SC ;
Das, SK .
DRUG DELIVERY, 2003, 10 (02) :73-77
[10]   Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: Immunogenicity and protection in mice [J].
Chiarantini, L ;
Argnani, R ;
Zucchini, S ;
Stevanato, L ;
Zabardi, P ;
Grossi, MP ;
Magnani, M ;
Manservigi, R .
VACCINE, 1997, 15 (03) :276-280